RNA-Engineered Cell Therapy With Cartesian's Dr. Murat Kalayoglu
Source: Bioprocess Online
![20_12_BPO_BusBiotech_Social_ep48 20_12_BPO_BusBiotech_Social_ep48](https://vertassets.blob.core.windows.net/image/1f4ceb72/1f4ceb72-a9a2-4722-a69b-de992099d95f/375_250-20_12_bpo_busbiotech_social_ep48.png)
Cartesian President & CEO Murat Kalayoglu, M.D., Ph.D. has led three of his company's six autoimmune, oncology, and respiratory candidates through Phase I/II clinical trials and two more of them are on the cusp of entering Phase I this year. With so many programs in and entering the clinic, he's a great choice for a conversation on GMP expectations for phase I first-in-human trials. Glean insight from Cartesian's experiences and learn about the company's novel approach to RNA-engineered cell therapies for oncology and beyond on this episode of The Business of Biotech.
access the Podcast!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more